Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

CJC-1295 vs tesamorelin

Tesamorelin (Egrifta) is an FDA-approved GHRH analog used to reduce abdominal fat in HIV patients with lipodystrophy. It has a modified amino acid sequence that improves stability over natural GHRH. Tesamorelin's half-life falls between Sermorelin and CJC-1295

This comparison does not assign a generated winner or score.

  • Tesamorelin (Egrifta) is an FDA-approved GHRH analog used to reduce abdominal fat in HIV patients with lipodystrophy. It has a modified amino acid sequence that improves stability over natural GHRH.
  • Tesamorelin's half-life falls between Sermorelin and CJC-1295, typically around 26-38 minutes. Its FDA approval gives it a more established safety profile for specific clinical applications.
  • For research purposes, CJC-1295 (particularly with DAC) offers longer duration of action and doesn't require the daily injections that tesamorelin protocols typically use.
More references

Related material

Comparison

CJC-1295 vs other GHRH analogs

CJC-1295 isn't the only option for researchers interested in GHRH modulation. Understanding how it compares to alternatives helps in selecting the right peptide for specific goals.

View details →
Comparison

CJC-1295 vs Sermorelin

Sermorelin is a 29-amino acid peptide corresponding to the first 29 amino acids of natural GHRH. Unlike CJC-1295, it lacks the modifications that provide DPP-IV resistance. The re…

View details →
Comparison

CJC-1295 with DAC vs without DAC

Here's where most guides fail researchers. CJC-1295 exists in two distinct forms, and choosing the wrong one for your goals can mean the difference between optimal results and was…

View details →
Comparison

CJC-1295 vs synthetic HGH

Synthetic human growth hormone (somatropin) directly introduces GH into the body, bypassing the pituitary entirely. HGH produces predictable, dose-dependent GH elevation, but it a…

View details →